文献速递肝病

中低收入国家消除病毒性肝炎的障碍与克服策略

Barriers to viral hepatitis elimination and new strategies to overcome them in low- and middle-income countries.
PubMed 文献 · J Hepatol · 2026-09-06

本文综述中低收入国家在消除乙肝、丙肝和丁肝过程中照护连续体各环节的障碍,包括卫生系统薄弱、实验室基础设施有限、集中化照护模式、经济限制、污名化和碎片化项目。文章讨论简化诊疗路径、即时检测、自检、整合检测平台、分散化照护和任务分担等实用策略,并强调技术进步不足以解决问题,还需加强卫生系统并将肝炎服务整合到现有医疗项目中。

要点

  • 中低收入国家病毒性肝炎负担最重,消除进展不足。
  • 照护连续体从疫苗到随访各环节均存在缺口。
  • 需简化诊疗、分散照护并整合服务以克服障碍。

核心结论

  • 技术进步本身不足以消除病毒性肝炎,还需加强卫生系统、分散化照护模式并将病毒性肝炎服务整合到现有医疗项目中。

研究设计与样本

  • 本文为综述,分析中低收入国家病毒性肝炎照护连续体中的障碍并讨论克服策略。

主要发现

  • 中低收入国家承担最大疾病负担,尽管有高效预防工具、简化诊断和可负担抗病毒治疗,多数国家消除进展仍不足。
  • 照护连续体从疫苗接种、预防母婴传播到筛查、确诊检测、连接照护、启动治疗和长期随访全程存在缺口。
  • 卫生系统结构薄弱、实验室基础设施有限、集中化照护模式、经济限制、污名化和碎片化疾病专项规划持续阻碍大规模实施。

关键数值与推荐

  • 世界卫生组织目标是到2030年将病毒性肝炎作为公共卫生威胁消除。

临床怎么用

  • 可采用简化诊断和治疗路径、即时检测和近即时检测技术、自检、整合检测平台、分散化照护和任务分担等实用方法。
  • 需关注预防母婴传播、常规医疗体系服务不足人群的需求以及影响肝病进展的合并症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic infections with hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis D virus (HDV) are major causes of cirrhosis and hepatocellular carcinoma (HCC) worldwide. The greatest burden is borne by low- and middle-income countries (LMICs). Despite the availability of highly effective preventive tools, simplified diagnostics, and affordable antiviral therapies, progress toward the World Health Organization's (WHO) goal of eliminating viral hepatitis as a public health threat by 2030 is insufficient in most LMICs. Gaps persist throughout the entire care continuum, from vaccination and the prevention of mother-to-child transmission to screening, confirmatory testing, linkage to care, treatment initiation, and long-term follow-up. Structural weaknesses in health systems, limited laboratory infrastructure, centralised models of care, financial constraints, stigma, and fragmented disease-specific programmes continue to hinder large-scale implementation. This article examines the main barriers encountered across the viral hepatitis care cascade, from prevention and testing to treatment and long-term follow-up. It discusses practical approaches to overcoming them, including simplified diagnostic and treatment pathways, point-of-care and near-point-of-care technologies, self-testing, integrated testing platforms, decentralised care, and task sharing. Attention is given to the prevention of mother-to-child transmission, the needs of populations underserved by conventional healthcare systems, and comorbidities that influence liver disease progression. In conclusion, technological advances alone will not be sufficient. Progress will also depend on stronger health systems, decentralised models of care, and the integration of viral hepatitis services into existing healthcare programmes.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Vo-Quang E, Lemoine M, Pawlotsky JM, et al. Barriers to viral hepatitis elimination and new strategies to overcome them in low- and middle-income countries. J Hepatol. 2026. PMID: 42700819. doi:10.1016/j.jhep.2026.08.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。